Troy Bremer, Co-Founder, Chief Scientific Officer

Troy is co-founder and Chief Scientific Officer at Metronom Health, and has been an integral part of the company since its inception.

Troy is passionate about improving healthcare through innovation. His research background has involved the application of machine learning, statistical pattern recognition, modeling and biostatistics to molecular biology. He has expertise in the planning, management, analysis and execution of complex research and development programs.

Troy has extensive experience in diagnostic development and previously identified and validated several biomarker panels for disease prognosis and treatment response in oncology, leading to a number of publications and various patents. He is also co-founder and Chief Scientific Officer for PreludeDx, a Fjord Ventures portfolio company, founded in 2009 whose mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system. Prior to PreludeDx and Metronom Health, Troy worked at Lion Biosciences and Prediction Sciences where he served as Director of Research and Development.

Troy received his Doctorate in Biomedical Engineering from the University of California, San Diego.